CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
gemcitabine +1 moredrug
Likely dose
gemcitabine 1000 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00380588
NCT00380588Phase 2Completed
CompareCT.gov

A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer

Eli Lilly and Company·interventional·Posted Sep 26, 2006·Updated Nov 20, 2009

In Brief

A Phase 2 clinical trial evaluating gemcitabine and cisplatin for Biliary Tract Cancer. Completed, enrolled 84 participants across 7 sites.

Detailed Summary

To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2006
Enrollment StartSep 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.8 years ago

Interventions

gemcitabinedrug

1000 milligrams per square meter (mg/m2), intravenous (IV)

cisplatindrug

25 milligrams per square meter (mg/m2), intravenous (IV)